Has MAKO Surgical Become the Perfect Stock?
Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?
One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, then decide if MAKO Surgical (NASDAQ: MAKO ) fits the bill.
The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:
Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
Margins. Higher sales mean nothing if a company can't produce profits from them. Strong margins ensure that company can turn revenue into profit.
Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
Valuation. You can't afford to pay too much for even the best companies. By using normalized figures, you can see how a stock's simple earnings multiple fits into a longer-term context.
Dividends. For tangible proof of profits, a check to shareholders every three months can't be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.
Since we looked at MAKO Surgical last year, the company hasn't seen its score change. But investors weren't as lucky with its share price, which has plunged by half in the past year.
MAKO has become well-known for its RIO systems, which allow doctors to do orthopedic surgery robotically. Following in the steps of Intuitive Surgical (NASDAQ: ISRG ) and its da Vinci robotic surgical system, MAKO has tried to further the use of robotics in medicine for procedures that have become increasingly necessary for an active but aging population.
But 2012 has been a horrible year for MAKO. In announcing its first-quarter results, the company said that sales of systems had fallen well below expectations and lowered its guidance for the remainder of 2012. The second quarter brought even more disappointment, and most recently, news that privately held Blue Belt Technologies and its NavioPFS orthopedic robotic surgical system received FDA approval has pushed the stock down further.
Even worse, provisions of health-care reform could truly smack MAKO. Starting next year, a 2.3% excise tax on medical devices will take effect. Because the tax is on revenue rather than profits, it'll hit MAKO and Hansen Medical (NASDAQ: HNSN ) especially hard, as they're not making money even before the tax. Even big companies Medtronic (NYSE: MDT ) and Stryker (NYSE: SYK ) will suffer from the tax, with Stryker saying it would need to lay off 5% of its workforce in part due to its effects.
For MAKO to improve, it needs to get past controversies over its RIO systems and start boosting sales. If it can't, then MAKO may never be able to call itself a perfect stock.
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate out the best investments from the rest.
Learn more about MAKO's future by reading the Fool's premium research report on the company. Inside, Fool analyst and MAKO expert David Meier gives his scoop on whether MAKO is a buy after its big plunge in 2012. As an added bonus, David will keep you informed with a full year of updates and guidance on MAKO Surgical as news breaks. Click here now to learn more and start reading.